Search Results - "Faessel, M."

Phase I Study of the Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (TAK-924/MLN4924) in Patients with Advanced Solid Tumors by Sarantopoulos, John, Shapiro, Geoffrey I, Cohen, Roger B, Clark, Jeffrey W, Kauh, John S, Weiss, Glen J, Cleary, James M, Mahalingam, Devalingam, Pickard, Michael D, Faessel, Hélène M, Berger, Allison J, Burke, Kristine, Mulligan, George, Dezube, Bruce J, Harvey, R Donald

“…To determine the dose-limiting toxicities (DLTs) and maximum tolerated dose (MTD) of the investigational NEDD8-activating enzyme (NAE) inhibitor pevonedistat…”
Get full text

Medical Castration Using the Investigational Oral GnRH Antagonist TAK-385 (Relugolix): Phase 1 Study in Healthy Males by MacLean, David B, Shi, Hongliang, Faessel, Hélène M, Saad, Fred

“…Context: TAK-385 is a highly selective, oral, nonpeptide GnRH antagonist being investigated as a possible prostate cancer treatment. Objective: The objectives…”
Get full text

Pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, combined with azacitidine in patients with AML by Swords, Ronan T., Coutre, Steven, Maris, Michael B., Zeidner, Joshua F., Foran, James M., Cruz, Jose, Erba, Harry P., Berdeja, Jesus G., Tam, Wayne, Vardhanabhuti, Saran, Pawlikowska-Dobler, Iwona, Faessel, Hélène M., Dash, Ajeeta B., Sedarati, Farhad, Dezube, Bruce J., Faller, Douglas V., Savona, Michael R.

“…Pevonedistat (TAK-924/MLN4924) is a novel inhibitor of NEDD8-activating enzyme (NAE) with single-agent activity in relapsed/refractory acute myeloid leukemia…”
Get full text

Phase I Study of the Novel Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (MLN4924) in Patients with Relapsed/Refractory Multiple Myeloma or Lymphoma by Shah, Jatin J, Jakubowiak, Andrzej J, O'Connor, Owen A, Orlowski, Robert Z, Harvey, R Donald, Smith, Mitchell R, Lebovic, Daniel, Diefenbach, Catherine, Kelly, Kevin, Hua, Zhaowei, Berger, Allison J, Mulligan, George, Faessel, Hélène M, Tirrell, Stephen, Dezube, Bruce J, Lonial, Sagar

“…Evaluate the safety, pharmacokinetic profile, pharmacodynamic effects, and antitumor activity of the first-in-class investigational NEDD8-activating enzyme…”
Get full text

Pharmacokinetics, pharmacodynamics and safety assessment of multiple doses of soticlestat in healthy volunteers by Wang, Shining, Chen, Grace, Merlo Pich, Emilio, Affinito, John, Cwik, Michael, Faessel, Hélène M.

“…Aims Soticlestat, a first‐in‐class inhibitor of cholesterol 24‐hydroxylase (also known as cytochrome P450 46A1), is currently in development for the treatment…”
Get full text

The Oral Gonadotropin-releasing Hormone Receptor Antagonist Relugolix as Neoadjuvant/Adjuvant Androgen Deprivation Therapy to External Beam Radiotherapy in Patients with Localised Intermediate-risk Prostate Cancer: A Randomised, Open-label, Parallel-group Phase 2 Trial by Dearnaley, David P., Saltzstein, Daniel R., Sylvester, John E., Karsh, Lawrence, Mehlhaff, Bryan A., Pieczonka, Christopher, Bailen, James L., Shi, Hongliang, Ye, Zhan, Faessel, Hélène M., Lin, Huamao, Zhu, Yanyan, Saad, Fred, MacLean, David B., Shore, Neal D.

“…External beam radiotherapy (EBRT) with neoadjuvant/adjuvant androgen deprivation therapy (ADT) is an established treatment option to prolong survival for…”
Get full text

A Review of the Clinical Pharmacokinetics and Pharmacodynamics of Varenicline for Smoking Cessation by Faessel, Hélène M., Obach, R. Scott, Rollema, Hans, Ravva, Patanjali, Williams, Kathryn E., Burstein, Aaron H.

“…Varenicline tartrate (Chantix®/Champix®) is a selective partial agonist of the α 4 β 2 nicotinic acetylcholine receptor and is approved as an aid to smoking…”
Get full text

Population pharmacokinetics of pevonedistat alone or in combination with standard of care in patients with solid tumours or haematological malignancies by Faessel, Hélène M., Mould, Diane R., Zhou, Xiaofei, Faller, Douglas V., Sedarati, Farhad, Venkatakrishnan, Karthik

“…Aims A population pharmacokinetic (PK) analysis was conducted to quantify the impact of patient‐specific and concurrent medication factors on pevonedistat PK…”
Get full text

Phase I study assessing the mass balance, pharmacokinetics, and excretion of [14C]-pevonedistat, a NEDD8-activating enzyme inhibitor in patients with advanced solid tumors by Zhou, Xiaofei, Sedarati, Farhad, Faller, Douglas V., Zhao, Dan, Faessel, Hélène M., Chowdhury, Swapan, Bolleddula, Jayaprakasam, Li, Yuexian, Venkatakrishnan, Karthik, Papai, Zsuzsanna

“…Summary Pevonedistat (TAK-924/MLN4924) is an investigational small-molecule inhibitor of the NEDD8-activating enzyme that has demonstrated preclinical and…”
Get full text

Morphological segmentation of FIB‐SEM data of highly porous media by PRILL, T., SCHLADITZ, K., JEULIN, D., FAESSEL, M., WIESER, C.

“…Summary Nanoporous materials play an important role in modern batteries as well as fuel cells. The materials microstructure needs to be analyzed as it…”
Get full text

Population pharmacokinetic analysis of varenicline in adult smokers by Ravva, Patanjali, Gastonguay, Marc R., Tensfeldt, Thomas G., Faessel, Hélène M.

“…WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT? • Several clinical pharmacology studies have characterized the pharmacokinetics of varenicline in young adult and…”
Get full text

3D Modelling of random cellulosic fibrous networks based on X-ray tomography and image analysis by Faessel, M., Delisée, C., Bos, F., Castéra, P.

“…The microstructure of fibrous networks in low density wood-based fibreboards elaborated with various processes is observed by X-ray tomography. Image analysis…”
Get full text

Multiple-Dose Pharmacokinetics of the Selective Nicotinic Receptor Partial Agonist, Varenicline, in Healthy Smokers by Faessel, Hélène M., Gibbs, Megan A., Clark, David J., Rohrbacher, Kevin, Stolar, Marilyn, Burstein, Aaron H.

“…Varenicline is a novel and selective α4β2 nicotinic acetylcholine receptor partial agonist developed for smoking cessation. The primary objectives of this…”
Get full text

Segmentation of 3D microtomographic images of granular materials with the stochastic watershed by FAESSEL, M, JEULIN, D

“…Segmentation of 3D images of granular materials obtained by microtomography is not an easy task. Because of the conditions of acquisition and the nature of the…”
Get full text

Direct estimation of austenitic grain dimensions in heat affected zones of a martensitic steel from EBSD images by ALTENDORF, H., FAESSEL, M., JEULIN, D., LATOURTE, F.

“…Summary In the context of automated analyses of electron‐backscattered‐diffraction images, we present in this paper a novel method to automatically extract…”
Get full text

Modelling mesoporous alumina microstructure with 3D random models of platelets by WANG, H., PIETRASANTA, A., JEULIN, D., WILLOT, F., FAESSEL, M., SORBIER, L., MOREAUD, M.

“…Summary This work focuses on a mesoporous material made up of nanometric alumina ‘platelets’ of unknown shape. We develope a 3D random microstructure to model…”
Get full text

Pharmacokinetic-Pharmacodynamic Modeling of the Effect of Varenicline on Nicotine Craving in Adult Smokers by Ravva, Patanjali, Gastonguay, Marc R., Faessel, Hélène M., Lee, Theodore C., Niaura, Raymond

“…Varenicline has been shown to significantly reduce craving and several aspects of smoking reinforcement in clinical trials, compared with placebo. This is the…”
Get full text

Effect of Human Renal Cationic Transporter Inhibition on the Pharmacokinetics of Varenicline, a New Therapy for Smoking Cessation: An In Vitro–In Vivo Study by Feng, B, Obach, RS, Burstein, AH, Clark, DJ, Morais, SM, Faessel, HM

“…Varenicline is predominantly eliminated unchanged in urine, and active tubular secretion partially contributes to its renal elimination. Transporter inhibition…”
Get full text

Single-Dose Pharmacokinetics of Varenicline, a Selective Nicotinic Receptor Partial Agonist, in Healthy Smokers and Nonsmokers by Faessel, Hélène M., Smith, Bill J., Gibbs, Megan A., Gobey, Jason S., Clark, David J., Burstein, Aaron H.

“…Varenicline is a novel and selective α4β2 nicotinic receptor partial agonist that is under development for smoking cessation. The primary objectives of this…”
Get full text

Pharmacokinetics, Safety, and Tolerability After Single and Multiple Oral Doses of Varenicline in Elderly Smokers by Burstein, Aaron H., Fullerton, Terence, Clark, David J., Faessel, Hélène M.

“…Varenicline is a novel selective α4β2 nicotinic acetylcholine partial agonist developed for smoking cessation. This study investigated the single‐ and…”
Get full text